Focal Segmental Glomerulosclerosis Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
TVTX | B | Travere Therapeutics, Inc. | 0.40 | |
ZVSA | F | ZyVersa Therapeutics, Inc. | -4.98 |
Related Industries: Biotechnology Drug Manufacturers - Major
Related ETFs - A few ETFs which own one or more of the above listed Focal Segmental Glomerulosclerosis stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBP | A | BioShares Biotechnology Products Fund | 3.71 | |
PTH | D | Invesco DWA Healthcare Momentum ETF | 1.11 | |
FFTY | B | Innovator IBD 50 Fund ETF | 0.98 | |
FSCC | D | Trust Federated Hermes MDT Small Cap Core ETF | 0.78 | |
DWAS | B | PowerShares DWA SmallCap Technical Leaders Portfolio | 0.45 |
Compare ETFs
- Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a histopathologic finding of scarring (sclerosis) of glomeruli and damage to renal podocytes. This process damages the filtration function of the kidney, resulting in protein loss in the urine. FSGS is a leading cause of excess protein loss—nephrotic syndrome—in children and adults. Signs and symptoms include proteinuria, water retention, and edema. Kidney failure is a common long-term complication of disease. FSGS can be classified as primary versus secondary depending on whether a particular toxic or pathologic stressor can be identified as the cause. Diagnosis is established by renal biopsy, and treatment consists of glucocorticoids and other immune-modulatory drugs. Response to therapy is variable, with a significant portion of patients progressing to end-stage kidney failure. FSGS is estimated to occur in 2-3 persons per million, with males and African peoples at higher risk .
Popular Now
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Featured Articles